1006376-62-0

Basic information

• Product Name: (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide
• Synonyms: (1R,2R)-2-(3,4-difluorophenyl)cyclopropane-1-carboxamide;(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide;Cyclopropanecarboxamide, 2-(3,4-difluorophenyl)-, (1R,2R)-
• CAS NO: 1006376-62-0
• Molecular Formula: C₁₀H₉F₂NO
• Molecular Weight: 197
• EINECS: -0
• Mol File: 1006376-62-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 347.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.366±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 16.43±0.40(Predicted)
• CAS DataBase Reference: (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide(1006376-62-0)
• EPA Substance Registry System: (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide(1006376-62-0)

Safety Data

• Hazardous Substances Data: 1006376-62-0(Hazardous Substances Data)

Usage

Description

(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide is an organic compound with a unique cyclopropane carboxamide structure, featuring a 3,4-difluorophenyl group. It is characterized by its stereochemistry, with the R configuration at both the first and second carbon atoms. (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide has potential applications in various fields due to its structural properties and interactions with other molecules.

Uses

Used in Pharmaceutical Industry:
(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide is used as a key intermediate in the synthetic preparation of ticagrelor derivatives. These derivatives serve as antiplatelet agents, which are crucial in the prevention and treatment of conditions related to blood clotting, such as heart attacks and strokes.
Application Reason:
The compound's unique structure allows it to effectively inhibit ADP-induced platelet aggregation, a process that can lead to the formation of blood clots. By incorporating this compound into the synthesis of ticagrelor derivatives, researchers can develop more potent and selective antiplatelet agents, potentially improving patient outcomes and reducing the risk of clot-related complications.

Upstream product

• 1450916-28-5 (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carbonitrile 
• 1006376-61-9 (1R,2R)-2-(3,4-difluorophenyl)-1-cyclopropanecarboxylic acid ethyl ester 
• 451455-95-1 diethyl (3,4-difluoro-benzyl)phosphonate 
• 77287-34-4 formamide 
• 85118-01-0 alpha-bromo-3,4-difluorotoluene 
• 168267-41-2 (3,4-difluorophenyl)boronic acid 
• 1459720-02-5 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanoic acid methyl ester 
• 1248202-12-1 4-keto-4-(3,4-difluorophenyl)butyric acid methyl ester 
• 1267369-02-7 isopropyl 4-(3,4-difluorophenyl)-4-oxobutanoate 
• 898752-22-2 C₁₂H₁₂F₂O₃ 
• 51336-95-9 2-chloro-1-(3,4-difluorophenyl)ethan-1-one 
• 367-11-3 ortho-difluorobenzene 

Downstream Products

• 1006614-49-8 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine 
• 274693-27-5 ticagrelor 
• 220347-05-7 AR-C₁₂₄₉₁₀XX 
• 274693-49-1 (3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 1381841-44-6 2-((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy) thyl carbonate 
• 1381841-46-8 2-((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy)ethyl isobutyl carbonate 
• 1381841-52-6 (1S,2S,3S,4R)-4-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl butyrate 
• 1381841-55-9 (1S,2S,3S,4R)-4-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl ethyl carbonate 
• 1381841-56-0 (1S,2S,3S,4R)-4-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl isobutyl carbonate 
• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 1381841-39-9 2-((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy)ethyl butyrate 
• 1402222-66-5 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine hydrochloride 
• 2096989-55-6 [1S-[1a,2a,3β(1S*,2R*),5B]]-3-[7-[2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 
• 376608-71-8 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine (2R)-2-hydroxy-2-phenylacetic acid salt 

Relevant articles and documents

Preparation method of phenyl-containing compound

The present invention discloses a method for preparing an phenyl-containing compound. The present invention provides a method for preparing a compound shown in formula I, comprising the following steps: in the presence of formamide or acetamide, in the pr

Preparation method of ticagrelor key intermediate aromatic cyclopropanamide

The invention discloses a preparation method of a ticagrelor key intermediate, aromatic cyclopropanamide. The method comprises the following steps: with (1R,2R)-2-(3,4-difluorophenyl)-1-cyclopropyl formate (I) as an initial raw material, carrying out tran

Preparation method of ticagrelor

The invention discloses a preparation method of ticagrelor. The preparation method comprises the following steps: (1) preparation of ticagrelor intermediate product 1-TK acid; (2) preparation of ticagrelor intermediate product 2-TK-amide; (3) preparation of ticagrelor intermediate product 3-TK-amino compound hydrochloride; (4) preparation of ticagrelor intermediate product 4-TK-amino compound R-tartrate; ( 5) preparation of ticagrelor intermediate product 5-TK-amino compound L-mandelate; and (6) preparation of ticagrelor-TK. The preparation method has the advantages of cost advantage, mature and stable process, stable product quality, and safe and reliable production process.